Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

Multiple Myeloma Clinical Trial

Official title:

A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01478581
• Other study ID #: PCYC-1111-CA
• Secondary ID: PCI-32765
• Status: Completed
• Phase: Phase 2
• Start date: March 2012
• Est. completion date: August 2018

Study information

• Verified date: October 2019
• Source: Pharmacyclics LLC.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to determine the efficacy of PCI-32765, both as a single agent and in combination with dexamethasone, in subjects with relapsed or relapsed and refractory Multiple Myeloma (MM)

Description:

Bruton's tyrosine kinase (Btk) is an enzyme that is present in hematopoietic cells other than T cells and is necessary for downstream signal transduction from various hematopoietic receptors including the B cell receptor as well as some Fc, chemokine, and adhesion receptors, and is crucial for both B cell development and osteoclastogenesis. Although down-regulated in normal plasma cells, Btk is highly expressed in the malignant cells from many myeloma patients and some cell lines. PCI 32765 is a potent and specific inhibitor of Btk currently in Phase 2 clinical trials. The current study is designed and intended to determine the effects of PCI-32765 in subjects with MM.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 92
• Est. completion date: August 2018
• Est. primary completion date: August 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of symptomatic MM with measurable disease, defined here as having at least one of the following:

1. Serum monoclonal protein (M-protein) =0.5 g/dL as determined by serum protein electrophoresis (SPEP)

2. Urine M-protein =200 mg/24 hrs

3. Serum free light chain (FLC) assay: involved FLC level =10 mg/dL (=100 mg/L) provided serum FLC ratio is abnormal

• Relapsed or relapsed and refractory MM after receiving at least 2 but no more than 5 previous lines of therapy, 1 of which must be an immunomodulator.

• Refractory myeloma (to most recent treatment) is defined as disease that is nonresponsive while on treatment or progressive disease within 60 days after the completion of preceding treatment. Nonresponsive disease is defined as either failure to achieve minimal response or development of progressive disease while on therapy.

• Men and women =18 years of age.

• ECOG performance status of = 1.

Exclusion Criteria:

• Subject must not have primary refractory disease defined as disease that is nonresponsive in subjects who have never achieved a minor response (MR) or better with any therapy.

• Polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome, osteosclerotic myeloma, or Crow-Fukase syndrome.

• Plasma cell leukemia.

• Primary amyloidosis.

• Certain exclusions on prior therapy.

• ANC <0.75 x 10^9/L independent of growth factor support.

• Platelets <50 x 10^9/L) independent of transfusion support.

• AST or ALT =3.0 x upper limit of normal (ULN).

• Total bilirubin >2.5 x ULN, unless due to Gilbert's syndrome.

• Creatinine >2.5 mg/dL.

• Unable to swallow capsules or disease significantly affecting gastrointestinal function.

• Requires anti-coagulation with warfarin or a vitamin K antagonist. Requires treatment with strong CYP3A4/5 inhibitors.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• PCI-32765

• Dexamethasone

Locations

Country	Name	City	State
United States	SITE-8	Ann Arbor	Michigan
United States	SITE-5	Baltimore	Maryland
United States	SITE-4	Boston	Massachusetts
United States	SITE-11	Dallas	Texas
United States	SITE-6	Hackensack	New Jersey
United States	SITE-13	La Jolla	California
United States	SITE-1	Nashville	Tennessee
United States	SITE-10	New York	New York
United States	SITE-3	New York	New York
United States	SITE-2	Saint Louis	Missouri
United States	SITE-9	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Pharmacyclics LLC.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Clinical Benefit Response (CBR)	The clinical benefit response (CBR) rate, defined as the proportion of subjects who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), or minimal response (MR) as assessed by the modified International Myeloma Working Group (IMWG) response criteria	From the date of first study treatment until disease progression per IMWG, up to 60 months
Secondary	To Evaluate the Efficacy of PCI-32765 by Assessing ORR	The objective response rate, defined as the proportion of subjects who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR), as assessed by the modified International Myeloma Working Group (IMWG) response criteria.	From the date of first study treatment until disease progression per IMWG, up to 60 months
Secondary	Pharmacokinetics (PK). (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Maximum Observed Plasma Concentration (Cmax)	Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Maximum observed plasma concentration of ibrutinib during the dosing interval on Day 8.	Procedure was performed up to 60 weeks.
Secondary	Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Time to Maximum Observed Plasma Concentration (Tmax).	Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Time to corresponding maximum observed plasma concentration of ibrutinib during the dosing interval on Day 8.	Procedure was performed up to 60 weeks.
Secondary	Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24h).	Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Ibrutinib AUC0-24h calculated using linear trapezoidal summation after dosing from time 0 to 24 hours on Day 8.	Procedure was performed up to 60 weeks.
Secondary	Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Terminal Elimination Half-life (t1/2,Term).	Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Ibrutinib terminal elimination half-life associated with the terminal slope (?z) of the semi-logarithmic plasma concentration-time curve, calculated as 0.693/?z on Day 8.	Procedure was performed up to 60 weeks.
Secondary	Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Accumulation Ratio for AUC0-24h (Acc. Ratio AUC0-24h)	Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Acc. Ratio calculated as Day 8 ibrutinib AUC0-24h/ Day 1 ibrutinib AUC0-24h.	Procedure was performed up to 60 weeks.
Secondary	Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Metabolite-to-Parent Ratio for Cmax (M/P Cmax)	Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Calculated as (PCI-45227 Cmax/PCI-45227 molecular weight)/(ibrutinib Cmax/ibrutinib molecular weight) on Day 8.	Procedure was performed up to 60 weeks.
Secondary	Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Metabolite-to-Parent Ratio for AUC0-24h (M/P AUC0-24h)	Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Calculated as (PCI-45227 AUC0-24h/PCI-45227 molecular weight)/(ibrutinib AUC0-24h/ibrutinib molecular weight) on Day 8.	Procedure was performed up to 60 weeks.
Secondary	Duration of Clinical Benefit Response (DCB)	DCB is defined as the time from first observation of response to the time of disease progression.	From the date of first study treatment until disease progression per IMWG, up to 60 months
Secondary	Duration of Response (DOR)	The time interval between the date of initial documentation of a response and the date of first documented evidence of progressive disease, death, or date of censoring for the subjects not progressed/died. The censoring date is the last adequate tumor assessment date.	up to 3 Years